Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size

Page 3

AbCellera amplifies IPO to $556m
The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.
Atsena actions $55m series A
University of Florida has backed a second round for Atsena, a vision loss therapy developer exploiting inventions the institution had originally licensed to Sanofi.
Revitope visits Junshi for $10m investment
Junshi Biosciences has invested in the University of Birmingham-founded cancer immunotherapy developer, building on a research collaboration deal.
Exo Therapeutics executes $25m series A
The exosite drug developer has launched publicly to advance research from Harvard University and Salk Institute for Biological Studies.
Singlera detects $150m in series B cash
Fudan University’s Furong Investment has co-led a round for Singlera Genomics, which will use the cash to advance its pipeline of cancer screening products.
Faze Medicines fades in with $81m
The neurodegenerative disorder drug developer has emerged from stealth to commercialise Howard Hughes Medical Institute research.
AbCellera accomplishes $483m initial public offering
Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.
InnoSkel sets out with $24.3m
Spun out of University of Côte d’Azur and Inserm, InnoSkel expects to fund clinical work to address a form of skeletal dysplasia that causes dwarfism.
Daily deal net: December 11, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Daily deal net: December 10, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

test reg

Login